PubMed Health. A service of the National Library of Medicine, National Institutes of Health.
A.D.A.M. Medical Encyclopedia [Internet]. Atlanta (GA): A.D.A.M.; 2013.
A.D.A.M. Medical Encyclopedia.
Alpha-1 antitrypsin (AAT) deficiency is a condition in which the body does not make enough of a protein that protects the lungs and liver from damage. The condition can lead to emphysema and liver disease.
Causes, incidence, and risk factors
Alpha-1 antitrypsin (AAT) is a type of protein called a "protease inhibitor." It is made in the liver and it works to protect the lungs and liver.
AAT deficiency means there is not enough of this protein in the body. It is caused by a genetic defect. The condition is most common among Europeans and North Americans of European descent.
Studies show that AAT deficiency may be more common than was once thought.
Adults with severe deficiency will develop emphysema, often before age 40. Smoking can increase the risk of emphysema. Other patients can have higher levels of AAT in their blood, and therefore have a less severe condition.
Persons with this deficiency may also develop liver disease.
Symptoms
- Shortness of breath with and without exertion, and other symptoms of chronic obstructive pulmonary disease (COPD)
- Symptoms of severe liver disease ( cirrhosis)
- Unintentional weight loss
Signs and tests
A physical examination may reveal a barrel-shaped chest, wheezing, or decreased breath sounds. The following tests may also help with diagnosis:
- Alpha-1 antitrypsin blood test
- CT scan of the chest
- Genetic testing
- Lung function test
Your doctor may suspect you of having this condition if you develop:
- Emphysema before age 45
- Emphysema but have never smoked or been exposed to toxins
- Emphysema and you have a family history of the condition
- Liver disease or hepatitis and no other cause can be found
- Liver disease or hepatitis and you have a family history of liver disease
Treatment
Treatment for AAT deficiency involves replacing the missing AAT protein. The protein is given through a vein each week. However, it is not yet well known who may benefit from such therapy.
If you smoke, you need to quit.
Other treatments for emphysema and cirrhosis are also used.
Expectations (prognosis)
Some people with this deficiency will not develop liver or lung disease. However, emphysema and cirrhosis can be life threatening.
Complications
- Cirrhosis or liver failure
- Emphysema
- Liver cancer
Calling your health care provider
Call your health care provider if you develop symptoms of AAT deficiency.
References
- Bacon BR. Inherited and metabolic hepatic disorders. In:Goldman L, Schafer AI, eds. Cecil Medicine. 24th ed. Philadelphia, Pa: Saunders Elsevier; 2011:chap 93.
- Niewoehner DE. Chronic obstructive pulmonary disease. In:Goldman L, Schafer AI, eds. Cecil Medicine. 24th ed. Philadelphia, Pa: Saunders Elsevier; 2011:chap 88.
- Shapiro SD, Reilly JJ Jr, Rennard SI. Chronic bronchitis and emphysema. In: Mason RJ, Broaddus CV, Martin TR, et al. Murray & Nadel's Textbook of Respiratory Medicine. 5th ed. Philadelphia, Pa: Saunders Elsevier; 2010:chap 39.
- Silverman EK, Sandhaus RA. Alpha-1 antitrypsin deficiency. N Engl J Med 2009;360:2749-2757. [PubMed: 19553648]
Review Date: 8/30/2012.
Reviewed by: David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine. Denis Hadjiliadis, MD, Assistant Professor of Medicine, Division of Pulmonary, Allergy and Critical Care, University of Pennsylvania, Philadelphia, PA. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M. Health Solutions, Ebix, Inc.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only — they do not constitute endorsementscof those other sites. © 1997–2011 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
Intravenous alpha‐1 antitrypsin augmentation therapy for treating patients with alpha‐1 antitrypsin deficiency and lung disease
Alpha‐1 antitrypsin deficiency is an inherited disorder that can cause lung disease. It affects about 1 in 1600 to 5000 people. Those with lung disease suffer from shortness of breath, reduced ability to exercise and wheezing. People who smoke are more seriously affected and have a greater risk of dying from the disease. We reviewed the benefits and harms of treating patients who have the form of the disease that affects the lungs with alpha‐1 antitrypsin extracted from human plasma. We found two randomised trials (total 140 patients) comparing this treatment with placebo for two to three years. All patients were ex‐smokers or had never smoked but had the genetic problem that carried a high risk of developing lung problems. Neither trial reported on the number of lung infections, hospital admissions or death from the disease. The studies found no difference between the two groups in quality of life or in number of exacerbations of the disease. The lung function deteriorated slightly less measured by CT scan, but slightly more measured by forced expiratory volume in one second. Therapy with alpha‐1 antitrypsin cannot be recommended, in view of the lack of evidence of clinical benefit and the high cost of treatment.
Making smart health choicesDevelop the skills to assess health advice and make better-informed decisions about your health and managing illness.
- Alpha-1 antitrypsin deficiencyAlpha-1 antitrypsin deficiencyPubMed Health
Your browsing activity is empty.
Activity recording is turned off.
See more...
